A Phase 2 Open-Label Study of Danicopan (ACH-0144471) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy

被引：14
|
作者：
Kulasekararaj, Austin [1 ,2 ]
Risitano, Antonio M. [3 ]
Maciejewski, Jaroslaw P. [4 ]
Notaro, Rosario [5 ,6 ]
Browett, Peter [7 ]
Lee, Jong-Wook [8 ]
Huang, Mingjun [9 ]
Geffner, Michael [10 ]
Brodsky, Robert A. [11 ]
机构：
[1] Kings Coll Hosp London, Dept Haematol, London, England
[2] Kings Collge London, London, England
[3] Univ Naples Federico II, Naples, Italy
[4] Cleveland Clin Fdn, Dept Translat Hematol & Oncol Res, Taussig Canc Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA
[5] Azienda Osped Univ Careggi, Florence, Italy
[6] Inst Studio Prevenz & Rete Oncol, Florence, Italy
[7] Univ Auckland, Dept Mol Med & Pathol, Sch Med, Auckland, New Zealand
[8] Catholic Univ Korea, Dept Hematol, Seoul St Marys Hosp, Seoul, South Korea
[9] Achillion Pharmaceut Inc, New Haven, CT USA
[10] Achillion Pharmaceut Inc, Blue Bell, PA USA
[11] Johns Hopkins Univ, Dept Med, Div Hematol, Baltimore, MD USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-124748
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3514
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Impact of elosulfase alfa in patients with morquio A syndrome who have limited ambulation: An open-label, phase 2 study
    Harmatz, Paul R.
    Mengel, Eugen
    Geberhiwot, Tarekegn
    Muschol, Nicole
    Hendriksz, Christian J.
    Burton, Barbara K.
    Jameson, Elisabeth
    Berger, Kenneth I.
    Jester, Andrea
    Treadwell, Marsha
    Sisic, Zlatko
    Decker, Celeste
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2017, 173 (02) : 375 - 383
  • [32] Patient-Reported Outcomes (PROs) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Crovalimab and Eculizumab: Results from the Phase III Randomized COMMODORE 2 and COMMODORE 1 Trials
    Panse, Jens
    Cermak, Jaroslav
    Kyselova, Olena
    Gotoh, Akihiko
    Sahin, Fahri
    Schrezenmeier, Hubert
    Chang, Alice C.
    Gentile, Brittany
    Uguen, Marianne
    Han, Bing
    BLOOD, 2023, 142
  • [33] Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study
    de Latour, Regis Peffault
    Roeth, Alexander
    Kulasekararaj, Austin
    Scheinberg, Phillip
    Ueda, Yasutaka
    de Castro, Carlos M.
    Di Bona, Eros
    Schrezenmeier, Hubert
    Mc Langemeijer, Saskia
    Barcellini, Wilma
    Tavitian, Suzanne
    Panse, Jens
    Schafhausen, Philippe
    Mauad, Vitor Aq
    Kerloeguen, Cecile
    Levitch, Rafael
    Kumar, Rakesh
    Thorburn, Christine
    Maitra, Samopriyo
    Dahlke, Marion
    Risitano, Antonio M.
    BLOOD, 2022, 140 : 5 - 9
  • [34] Impact of elosulfase alfa in patients with Morquio syndrome type A who have limited ambulation: An open-label, phase 2 study
    Harmatz, Paul R.
    Jester, Andrea
    Mengel, Eugen
    Treadwell, Marsha
    Burton, Barbara K.
    Berger, Kenneth I.
    Hendriksz, Christian J.
    Geberhiwot, Tarekegn
    Sisic, Zlatko
    Decker, Celeste
    MOLECULAR GENETICS AND METABOLISM, 2016, 117 (02) : S55 - S55
  • [35] Results from a phase 3, multicenter, noninferiority study of ravulizumab (ALXN1210) versus eculizumab (ECU) in adult patients (PTS) with paroxysmal nocturnal hemoglobinuria (PNH) naive to complement inhibitors (CI)
    Schrezenmeier, H.
    Lee, J. W.
    Rottinghaus, S. T.
    Lee, Lee L. W.
    Pessoa, V.
    Gualandro, S.
    Fuereder, W.
    Ptushkin, V.
    de Fontbrune, Sicre F.
    Volles, L.
    Shafner, L.
    Damokosh, A. I.
    Aguzzi, R.
    Pradhan, R.
    Ortiz, S.
    Hill, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 332 - +
  • [36] Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial
    Risitano, Antonio M.
    Roth, Alexander
    Soret, Juliette
    Frieri, Camilla
    de Fontbrune, Flore Sicre
    Marano, Luana
    Alashkar, Ferras
    Benajiba, Lina
    Marotta, Serena
    Rozenberg, Izabela
    Milojevic, Julie
    End, Peter
    Nidamarthy, Prasanna K.
    Junge, Guido
    de Latour, Regis Peffault
    LANCET HAEMATOLOGY, 2021, 8 (05): : E344 - E354
  • [37] Trial in Progress: An Open-Label, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104 in Complement Inhibitor-Naive Subjects with Paroxysmal Nocturnal Hemoglobinuria
    Zhang, Fengkui
    Han, Bing
    He, Guangsheng
    Zhou, Hu
    Wang, Chunrong
    Yue, Changhe
    Ma, Jay
    Rabe, Martin
    Fu, Helen
    He, Chaomei
    Tsui, Ping
    Wu, Jingtao
    Beddingfield, Frederick
    Song, Wenru
    Lee, Richard
    BLOOD, 2022, 140 : 11459 - 11460
  • [38] The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: Results of a prospective, multicenter, open-label study
    Gottlieb, Alice B.
    Kalb, Robert E.
    Blauvelt, Andrew
    Heffernan, Michael P.
    Sofen, Howard L.
    Ferris, Laura Korb
    Kerdel, Francisco A.
    Calabro, Stephen
    Wang, Jim
    Kerkmann, Urs
    Chevrier, Marc
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 67 (04) : 642 - 650
  • [39] ORAL IPTACOPAN MONOTHERAPY HAS SUPERIOR EFFICACY TO ANTI-C5 THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND RESIDUAL ANEMIA: RESULTS FROM THE PHASE III APPLY-PNH STUDY
    Risitano, Antonio Maria
    Roeth, Alexander
    Kulasekararaj, Austin
    Scheinberg, Phillip
    Ueda, Yasutaka
    de Castro, Carlos
    Di Bona, Eros
    Griffin, Morag
    Langemeijer, Saskia M. C.
    Schrezenmeier, Hubert
    Barcellini, Wilma
    Mauad, Vitor A. Q.
    Panse, Jens
    Schafhausen, Philippe
    Tavitian, Suzanne
    Beggiato, Eloise
    Gaya, Anna
    Huang, Wei-Han
    Kitawaki, Toshio
    Kutlar, Abdullah
    Maciejewski, Jaroslaw
    Notaro, Rosario
    Pullarkat, Vinod
    Schubert, Joerg
    Terriou, Louis
    Uchiyama, Michihiro
    de Fontbrune, Flore Sicre
    Marano, Luana
    Alashkar, Ferras
    Gandhi, Shreyans
    Kerloeguen, Cecile
    Levitch, Rafael
    Kumar, Rakesh
    Thorburn, Christine
    Maitra, Samopriyo
    Dahlke, Marion
    de Latour, Regis Peffault
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 121 - 123
  • [40] A PHASE 2, OPEN-LABEL, MULTICENTER STUDY OF ELOTUZUMAB MONOTHERAPY IN PATIENTS WITH HIGH-RISK SMOLDERING MULTIPLE MYELOMA
    Richardson, P.
    Wong, E.
    Stockerl-Goldstein, K.
    Rosenbaum, C.
    Dhodapkar, M.
    Jou, Y. M.
    Lynch, M.
    Robbins, M.
    Bleickardt, E.
    Jagannath, S.
    HAEMATOLOGICA, 2016, 101 : 328 - 329
12345